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ABSTRACT 
 
Wound healing is a complex process characterised by the repair and reconstitution of lost or 
damaged tissue. By the mid 1990s, several methods were proposed to enhance wound 
healing of surgical sites by introducing high concentrations of human platelets to these 
areas. In the early 21st century, Choukroun et al (2006b) introduced a new type of platelet 
concentrate that was devoid of any additives, and required no specialised equipment for its 
production. This concentrate was termed Platelet-rich fibrin (PRF) and although various 
aspects of this biomaterial had been studied, very little is currently known about its storage 
properties. Aim: To determine whether storage time had a significant effect on the platelet 
concentration of Choukroun’s PRF Method: A total of 30 patients were enrolled into the 
study. Three blood samples of 10ml each were drawn from each patient. Two of the blood 
samples (Group A and Group B) were centrifuged to form PRF. The third sample was used to 
measure the baseline blood platelet concentration and was therefore not centrifuged. After 
PRF had formed in both test groups, it was removed from the test tubes at 2 different times 
i.e. immediately after centrifuge (Group A) or after 60 min of storage in the blood collecting 
tube (Group B). The remaining blood was then tested for platelet concentration and 
compared to each other and the baseline reading. Results: 14 males and 16 females 
participated in the study (average age 41.7 years). A mean blood platelet concentration of 
282.8 ± 58.3 × 109/L was recorded for the baseline reading. Group A had a mean blood 
platelet concentration 7.9 ± 3.03 × 109/L. Group B had a mean blood platelet concentration 
of 4.0 ± 1.93 × 109/L. A statistically significant difference was seen between Groups A and B 
(p < 0.0001). Conclusions: Storage time has a significant effect of the platelet concentration 
of PRF. If stored over a period of 60 min, the platelet concentration of PRF increases. 
Further research is required to determine whether this finding is clinically significant. 
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Chapter 1 
Introduction 
 
Wound healing is a complex process characterised by the repair and reconstitution of lost or 
damaged tissue. It involves a number of soluble chemical mediators as well as blood and 
parenchymal cells that interact with the extracellular matrix in three overlapping 
component phases. These phases are essentially controlled by the release of cytokines and 
growth factors (GFs) which stimulate cell migration and maturation required for tissue 
repair. Blood platelets are critical storage components of these chemical mediators and 
therefore play a crucial role in wound healing.  
By the mid 1990s, several methods were proposed to enhance wound healing of surgical 
sites by introducing high concentrations of human platelets to these areas. It was assumed 
that platelets optimised wound healing by enhancing the amount of growth factors that 
were necessary for tissue growth. The most common type of platelet concentrate used in 
these procedures was platelet-rich-plasma (PRP). This concentrate, first described by Oz et 
al (1992) was an autologous blood-derived product that was formed from the patients’ own 
blood and was initially intended to be used as a fibrin glue in patients undergoing cardiac 
surgery. However, further investigation revealed that it had enhanced wound healing 
properties and several researchers exploited this property in a variety of clinical procedures. 
Whitmen et al (1997) was the first to describe its use in the management of maxillofacial 
procedures and, in 1998, Marx et al described its use in bone augmentation procedures.  
By the early part of the 21st century, the use of PRP to enhance bone augmentation in 
maxillofacial and dental implant procedures was commonplace, and several techniques had 
subsequently been developed to manufacture the product. However, the majority of these 
techniques required specialised equipment as well as animal-derived additives. Because of 
these disadvantages, researchers sought more tangible methods of producing PRP.  
Choukroun et al (2006) introduced a new type of platelet concentrate that differed 
significantly from other platelet concentrates in that it was devoid of any additives, and 
 
 
 
 
  
required no specialised equipment for its production. This new platelet concentrate was 
termed platelet-rich-fibrin (PRF). From its initial inception, PRF has extensively been studied 
and is now regarded as being a biological scaffold different to PRP. However, even though 
the use of PRF is starting to gain widespread acceptance, several questions regarding its 
biological stability and clinical efficacy remain unanswered. This study is an attempt to 
answer some of these questions. 
  
 
 
 
 
  
Chapter 2 
Literature Review 
Introduction 
Platelets and fibrin are essential components for normal haemostasis, and for many years it 
was assumed that this was their only function. However, recent evidence suggests that 
these elements have a much wider range of functions, and it is now accepted that they play 
a significant role in wound healing and microbial defence (Dohan Ehrenfest et al., 2010). 
These newly discovered properties have led to the development of several blood-derived 
products, consisting of concentrated platelets, that are used to enhance wound healing in 
both surgical and non-surgical procedures (Dohan Ehrenfest et al., 2009). Numerous 
techniques exist to prepare these concentrates, however, no single standardised method 
has been universally accepted. In order to further improve and enhance the efficacy of 
platelet concentrates, an essential understanding of platelets, fibrin, and their biological 
behaviour as concentrates, is required.  
The physiology of human platelets and fibrin  
Platelets 
Platelets are anucleate, discoid shaped blood cells (actually cellular fragments) that are 
derived from megakaryocytes in the bone marrow. They enter the peripheral blood 
circulation where they circulate for about 7-10 days before ultimately being destroyed by 
the spleen and pulmonary vascular bed. The normal concentration of platelets varies 
amongst population groups, but on average is about 100-400 × 109/L of circulating blood 
(Ezeilo et al, 2002).  
Structurally, platelets consist of the following three identifiable zones: 
 A cytoskeleton or peripheral zone containing the plasma membrane, receptors 
and the open canalicular system (OCS).  
 A sol-gel zone that is centrally located and contains the cytoplasm and contractile 
proteins  
 
 
 
 
  
 An organelle zone made up of granules, lysosomes, mitochondria and 
cytoplasmic organelles 
The organelle zone has a high concentration of secretory granules, all of which play a part in 
platelet function. Among the three types of platelet secretory granules i.e. α–granules, 
dense granules, and lysosomes, the α–granule is the most abundant. There are 
approximately 50–80 α–granules per platelet, ranging in size from 200 - 500 nm (Blair and 
Flaumenhaft, 2009; Carlson and Roach Jr, 2002; Lacci and Dardik, 2010). The total α–granule 
membrane surface area per platelet is 14 μm2, about 8-times more than dense granules and 
approximately equal to that of the open canalicular system (OCS). The α–granules contain a 
variety of substances, including serotonin, which is a powerful vasoconstrictor. The 
remaining granules, the lysosomal granules, contain hydrolytic enzymes that dissolve 
phagocytosed debris. Platelet function is, therefore, directly related to the properties of 
their secretory granules (Blair and Flaumenhaft, 2009) .  
The role of platelets in normal haemostasis  
When a blood vessel is injured, it immediately contracts at the site of injury. At the same 
time platelets adhere to the site and form a temporary plug to stop blood loss. This plug 
formation is divided into 3 interrelated stages that includes platelet adhesion, a release 
reaction, and platelet aggregation. 
Platelet adhesion is trigged by the exposure of injured collagen, secondary to tissue injury. 
This results in changes in platelet shape from normal discoid to spherical, with a number of 
protruding long projections known as filipodia, thereby allowing better adhesion to the 
underlying collagen.  
The release reaction is characterised by the secretion of substances outside the platelet 
membrane. Although both α-granules and dense granules release proteins that are involved 
in coagulation, α-granules secrete polypepides that play a role in both primary and 
secondary haemostasis. Another important function of the α-granules is the secretion of 
adhesive proteins (fibrinogen and von Willebrand factor). These are essential for platelet-
platelet and platelet-endothelial interactions and are responsible for platelet aggregation 
(the third stage of platelet plug formation). Coagulation factors V, XI and XIII are also found 
in platelet granules, and are released upon platelet activation.  
 
 
 
 
  
Platelet α-granules contain the inactive precursor of thrombin, i.e. prothrombin, and 
significant stores of high molecular weight kininogens, which augment the intrinsic clotting 
cascade. In addition, platelets release inhibitory proteases, such plasminogen activator 
inhibitor-1 (PAI-1) and α2-antiplasmin, which limit plasmin-mediated fibrinolysis. 
Platelets also control the haemostatic process by secreting numerous proteins that 
antagonise the progression of coagulation. These include antithrombin, which cleaves 
activated clotting factors in both the intrinsic and extrinsic pathways, and C1-inhibitor, 
which degrades plasma kallikrein, factor XIa, and factor XIIa (Blair and Flaumenhaft, 2009).  
Platelets and inflammation 
Recent evidence also suggests that platelets may form an integral part of the inflammatory 
response (Blair and Flaumenhaft, 2009; Choukroun et al., 2006a). Platelet α–granules 
influence inflammation by secreting high concentrations of pro-inflammatory and immune-
modulating factors. These mediators induce recruitment, activation, chemokine secretion, 
and differentiation of other vascular and blood cells. In some cases, these chemokines 
provide feedback to stimulate chemokine receptors on the platelet surface, thereby causing 
platelet activation, secretion, and perpetuation of the inflammatory cycle. Activated 
platelets bind to circulating immune cells in the blood, and surface-adherent platelets 
facilitate the recruitment, rolling, and arrest of monocytes, neutrophils, and lymphocytes to 
the activated endothelium. Platelets have also been shown to play an important role in the 
recruitment of neutrophils in certain diseases (Blair and Flaumenhaft, 2009; Tözüm and 
Demiralp, 2003).  
Platelets as a host defence mechanism 
Platelets protect the host against certain pathogenic microorganisms by directly interacting 
with viruses, bacteria, fungi, and protozoa (Blair and Flaumenhaft, 2009; Dohan Ehrenfest et 
al., 2009; Choukroun et al., 2006a). This antimicrobial effect is further enhanced by their 
ability to bind to erythrocytes infected with plasmodium, thereby killing the infecting 
parasite. Platelets secrete a group of microbicidal proteins collectively referred to as 
“platelet microbicidal proteins”, all of which have direct antimicrobial effects. Many of the 
cytokines that are released during the normal physiological function of platelets, are also 
 
 
 
 
  
microbicidal and include diverse chemical chemokines such as CLCX7, CLCX4 and CLCX5. 
Other proteins that further enhance the antimicrobial effect of platelets include compliment 
and compliment binding proteins such as C3 and C4 precursors which participate in the 
compliment activation cascade (Blair and Flaumenhaft, 2009).   
The role of platelets in wound healing 
The wound healing potential of platelets is related to their ability to secrete a variety of 
growth factors (GFs) (Gassling et al., 2010; Jang et al., 2010; Kang et al., 2011; Lacci and 
Dardik, 2010). These are necessary for the recruitment of reparative cells to the affected 
area. Although these GFs are not unique to platelets, the rapidity with which platelets 
accumulate at sites of vascular injury, results in an accelerated rate of GF concentration. 
The GFs associated with platelets have been identified as vascular endothelium growth 
factor (VEGF), platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), 
epidermal growth factor (EGF), hepatocyte growth factor (HGF), insulin-like growth factor 
(IGF), and transforming-growth-factor-beta (TGF-beta), all of which play a role in replacing 
lost tissue, resurfacing of the wound, and restoring vascular integrity (Dohan Ehrenfest et 
al., 2009, 2010; Dohan et al., 2006; He et al., 2009; Blair and Flaumenhaft, 2009). PDGF is 
chemotactic for several cells, including polymorphonuclear leukocytes, macrophages, 
fibroblasts and smooth muscle cells. It also stimulates the replication of stem cells 
associated with fibroblasts and endothelial cells (thereby promoting angiogenesis) as well as 
the production of fibronectin, a cell adhesion molecule required for proper cellular 
proliferation and migration during healing. PDGF is also known to induce osteogenesis and 
stimulate hyaluronic acid that is associated with wound contraction and remodelling. TGF-β, 
the other major growth factor secreted by platelets, stimulates fibroblast chemotaxis and 
the production of collagen and fibronectin by cells. It also inhibits collagen degradation and 
increases the concentration of protease inhibitors, thereby favouring fibrogenesis (Carlson 
and Roach Jr, 2002). 
 
Fibrin 
 
 
 
 
  
Fibrin is the activated form of fibrinogen, and plays an integral role in platelet aggregation 
during haemostasis. It is present in plasma and in platelet α-granules, and is derived from 
fibrinogen by the enzymic action of thrombin. The initial step in this conversion from 
fibrinogen to fibrin, is the formation of soluble fibrin monomers that appear as loose fibrin 
strands. These are stabilised into insoluble fibrin polymers (via hydrogen bonds) by Factor 
XIIIa in the presence of calcium ions. This insoluble polymerised structure acts as a biologic 
glue capable of consolidating the initial platelet cluster and constitutes the first cicatricial 
matrix of the injured site (Ezeilo, 2002). This reinforces the haemostatic ability of the 
platelets and results in a protective wall along vascular breaches of the endothelium (Dohan 
et al., 2006). Fibrin therefore plays a significant role in the ability to concentrate platelets 
and their associated GFs.  
The development of platelet-concentrates and platelet-rich-plasma (PRP) 
The role of fibrin in haemostasis led to the development of many commercially available 
fibrin glues, or gels that are still currently used. These agents were initially described in the 
early 1970s and were designed to act as natural adhesives in the management of wound 
bleeding. Throughout the past four decades they have successfully been used in various 
surgical procedures including cardiothoratic surgery, plastic surgery and oral and 
maxillofacial surgery (Whitman et al, 1997).  
The principle of fibrin glue production is the polymerisation of fribrinogen in the presence of 
thrombin and calcium. They were originally produced using donor plasma, but due to the 
low concentration of fibrinogen in human plasma, the stability and quality of the fibrin glue 
that was produced, was low (Raja and Munirathnam, 2008). Modern fibrin glues have 
sought to improve these properties, but have often been criticised for their high cost, 
requirement for donors, the use of animal-derived products, and the ability to transmit 
disease (Dohan et al., 2006).   
Mehmet Oz and the “new autologous glue” 
Due to the various disadvantages associated with the initial preparations of fibrin glue, 
researchers sought ways to improve the product during the early 1990s. In 1992, Oz et al 
published a seminal paper in which a new method of fibrin glue preparation was introduced. 
 
 
 
 
  
This method was unique in that it involved the use of platelet concentrates together with 
thrombin and calcium to form what the authors called “new autologous glue”. The platelet-
concentrate used in this method was derived from platelet-rich-plasma, which was readily 
available and routinely used to control haemorrhage for patients undergoing cardiac 
surgery. The platelet-rich-plasma was prepared by collecting whole blood from the patient 
and centrifuging it at 3000 rpm for 15 minutes, after which the red blood cells would be 
separated from the platelet-rich-plasma. Oz et al (1992) and colleagues then extracted 20 
ml of the platelet-rich-plasma and added calcium chloride and bovine thrombin to it in an 
effort to stimulate clot formation. After various trials involving both humans and animals, 
the authors concluded that their new method of autologous glue formation had several 
advantages over traditional methods of preparation. These included: 
1. Minimal cost was associated with the procedure due to the fact that platelet-rich-
plasma was readily available 
2. The risk of viral transmission from the use of infected blood was eliminated 
3. The source material was easily obtained  
4. The fibrin glue was autologous 
Even though the new method promised a simpler way of obtaining fibrin glue, the authors 
cautioned against using it in patients with an allergy to bovine thrombin. 
The birth of platelet-rich-plasma (PRP) 
A year after Oz et al (1992) published his article, Hood et al (1993) and later Hill et al (1993), 
presented the findings in the Annual Proceedings of the American Academy of 
Cardiovascular Perfusion of a “newly developed autologous platelet-concentrated fibrin 
glue” that had wound healing properties. This was the first time wound healing properties 
had been linked to platelet concentrated gels. Four years later, in 1997, Whitman et al 
introduced the use of platelet concentrated gels to enhance wound healing in various 
maxillofacial procedures. These procedures included mandibular reconstruction, adjuvant 
implant augmentation procedures, sinus lifts, reparation of Schnidarian membrane tears, 
the reconstruction of oral-antral fistulas and the control of haemorrhage. The platelet gel 
used in this case was similar to that previously described by Oz et al (1992), with minor 
modifications made to the preparation protocol.  
 
 
 
 
  
In 1998, Marx and colleagues introduced the term “platelet-rich-plasma” or “PRP” to 
describe platelet concentrated gels. This term, still in use today, refers to the platelet 
concentrated gel or modifications thereof that was initially proposed by Oz et al (1992). 
However, it must be borne in mind that the use of the term “platelet-rich-plasma”, was 
already in use and referred to platelet extracts used to control haemorrhage during surgery. 
Ultimately, this has led to confusion in the literature, with Dohan Ehrenfest et al (2009) 
proposing a standardised nomenclature to denote various platelet concentrates.  This, 
however, has still not gained universal acceptance. 
By the year 2000, PRP had gained widespread acceptance as a viable treatment option for 
various maxillofacial and other extra-oral procedures. Although research has focused on 
PRPs ability to enhance bone healing, it has been used successfully for the reparation of 
dural tears, during and after facial plastic surgery, as a haemostatic and lymphostatic agent 
in radical neck dissection, enhancement of knee and lumbar fusions, the management of 
chronic wounds such as diabetic ulcers, the treatment of burns, snake and spider bites, in 
the treatment of various cardiothoracic procedures, in major and minor vascular surgery, 
and in other areas such as ophthalmology and urology (Jameson, 2007). 
By 2007, several theories of how PRP contributed to accelerated wound healing were 
advanced. Central to all of them was the ability of a high concentration of platelets to 
release several growth factors and other mediators to stimulate the preferential migration 
of undifferentiated stem cells to the wound site. Long-term clinical research has yet to verify 
whether these theories are justified.   
PRP preparation methods 
Since the original description of PRP preparation by Oz et al (1992), several modifications of 
this technique have been explored, and, even though minor differences in preparation 
techniques exist, common to all of them are the following:  
1) Blood is collected with anticoagulant just before or during surgery and is 
immediately processed by centrifugation. The time for platelet concentrate 
preparation is variable, but is always completed within an hour. A first centrifugation 
step is designed to separate the blood into three layers, red blood cells (RBCs) are 
 
 
 
 
  
found at the bottom, acellular plasma (PPP, platelet-poor plasma) is in the 
supernatant and a ‘buffy coat’ layer appears in between, in which platelets are 
concentrated.  
2) The next steps vary among the numerous protocols, but are an attempt to discard 
both the RBC layer and the PPP to collect only the ‘buffy coat’ layer.  
3) Finally, the residual platelet concentrate is applied to the surgical site with a syringe, 
together with thrombin and/or calcium chloride (or similar factors) to trigger platelet 
activation and fibrin polymerization (Dohan Ehrenfest et al., 2009).  
This variation in preparation protocol has led to the non-standardisation of PRP with the 
result that potential clinical differences may be seen with the various preparations used 
(Dohan Ehrenfest et al., 2009).  
Safety and efficacy  
The preparation of PRP is not purely autologous and the addition of various chemicals, some 
of which are animal-derived, are common to most of the preparation techniques employed 
today. These chemicals, often include bovine thrombin and calcium chloride and are added 
to stimulate platelet activation and GF release. Other agents include acid citrate dextrose-A 
(ACD-A) and citrate phosphate dextrose (CPD), both of which are used to support the 
metabolic needs of platelets in anticoagulated blood. The addition of these chemicals and 
other agents during the preparation of PRP has drawn criticism by various authors for their 
potential adverse effects (Dohan Ehrenfest et al., 2009).    
Critics of PRP preparation techniques highlight the fact that several studies show that 
exposure of surgical patients to bovine thrombin preparations may result in the generation 
of anti–bovine antibodies that cross-react with certain human coagulation factors (Ofosu et 
al., 2009). The generation of these antibodies is well documented and may also be seen in 
patients treated with human plasma–derived, or recombinant therapeutic proteins. 
Furthermore, the purity of bovine thrombin preparations have recently been questioned 
since they differ markedly in concentration (with the bovine thrombin content varying from 
>90% to <30% for various different preparations) (Ofosu et al., 2009).  
Clinically, the adverse effects of using bovine-derived products range from acute and 
delayed allergic reactions to coagulative and bleeding reactions, and both these have been 
 
 
 
 
  
documented with the use of PRP  (Wei et al., 2003). Although a decline in the adverse 
events associated with the use of these agents have been noted during the past decade, 
researchers attribute this decline to underreporting and a lack of adequate research data 
(Clark et al., 2010). 
The potential adverse effects of using bovine or donor-derived thombin is, therefore, a 
significant consideration in the preparation of platelet concentrates and has led to 
researchers seeking alternative means of creating viable preparation methods for these 
products. 
Joseph Choukroun and platelet-rich-fibrin (PRF) 
In the late 1990s, Joseph Choukroun (cited by Dohan et al, 2006) successfully developed a 
new technique to concentrate blood platelets for surgical use. The unique feature of this 
new preparation method was that it allowed for the development of a platelet concentrate 
without the use of any animal additives or additional chemicals. Choukroun referred to the 
platelet concentrate as “platelet-rich-fibrin (PRF)” and the new method of preparation, as 
“Choukroun’s PRF”. The nomenclature was chosen to distinguish this platelet concentrate 
from other current forms of PRP. The term Choukroun’s PRF, PRF and “PRF clot” have been 
used interchangeably in the literature and this trend has been continued in this thesis. 
Different from traditional methods of producing PRP, Dohan et al (2006) described PRF 
preparation as follows; 
1) Venous blood is collected from the patient in standard 10-ml anticoagulant-free 
blood collecting tubes (either glass tubes or silica coated plastic tubes). According to 
Dohan et al (2006), any type of dry glass tube (Terumo® Venoject® 10 mL) or glass-
coated plastic tube (Terumo® Venosafe® 10 ml, Becton Dickinson Vacutainer ® 10 ml 
or Greiner® Vacuette® 9 ml) may be used. 
2) The collected blood is immediately centrifuged in any standard tabletop centrifuge 
at a relative centrifugal force of 400 x g for 10-12 minutes (Dohan et al., 2006). The 
absence of anticoagulant implies the activation of most platelets of the blood sample 
in contact with the tube walls and the release of the coagulation cascades within a 
few minutes. Fibrinogen is initially concentrated in the upper part of the tube, before 
the circulating thrombin transforms it into fibrin. A fibrin clot is then obtained in the 
 
 
 
 
  
middle of the tube, just between the red corpuscles at the bottom and acellular 
plasma (PPP) at the top (Figure 1). Platelets are theoretically trapped in large 
numbers in the fibrin meshes (Gassling et al., 2010).  
3) This platelet concentrated clot, together with the upper part of the red blood cell 
layer, may then be then be separated for clinical use (10 ml blood typically yields 1 
ml PRF) (Dohan Ehrenfest et al., 2010b) (Figure 2). 
4) The PRF clot may also be compressed to form an “autogenous membrane” (Dohan 
Ehrenfest et al., 2010b) (Figure 3).  
When compared to traditional PRP, PRF is easier to prepare, requires no specialized 
equipment, uses no added “activators”, is free of animal additives, is less expensive, and 
requires less time before it can be clinically applied (Dohan et al., 2006; Dohan Ehrenfest et 
al., 2010). In addition, PRF can be easily manipulated into a membrane for use in a variety of 
surgical procedures.  
PRF: Structure, biological properties and clinical applications 
Once removed from the blood collecting tube, PRF appears as a clot that is composed of 
two main areas: a yellow portion constituting the main body, and a lower red portion 
constituting the upper most part of the red blood cell layer (Figure 2). Biological analysis 
shows that the yellow portion is made up of three major components, i.e. platelets, 
leukocytes, and fibrin. It is thought that the fibrin acts as a vehicle for these cells and other 
cytokines during the process of wound healing (Choukroun et al., 2006b; Dohan Ehrenfest et 
al., 2010a, 2010b; Gassling et al., 2010; Kang et al., 2010).  
Dohan Ehrenfestet al (2010b) noted that PRF had a distinct architecture with a specific 
cellular distribution. Rather than the cells being evenly distributed throughout the PRF clot, 
it was shown that the highest concentration of platelets and leukocytes were found in the 
yellow area just above the red blood cell layer, with the concentration and homogeneity of 
cells, becoming progressively less as the distance from the red blood cell layer increased 
(Dohan Ehrenfest et al., 2010b).  
 
 
 
 
  
 
Figure 1: A-Acellular layer, B-PRF clot, C-RBC layer 
 
Figure 2: PRF clot  
 
 
 
 
  
 
Figure 3: PRF membrane 
This physical distribution of platelets is therefore specific for this type of platelet 
concentrate. For this reason, it has been suggested that PRF membranes be overlapped 
during its clinical application in order to maximise its efficacy.  
A recent analysis of the concentration of platelets found in PRF preparations showed that it 
trapped 97% of the total platelets available (Dohan Ehrenfest al., 2010b). Different to other 
platelet concentrates, PRF is also designed to retain a high concentration of leukocytes. 
These leukocytes are thought to undergo degranulation during clot formation, thereby 
activating a number of cytokines that protect the wound from infection (Dohan et al., 2006). 
Up to 50% of available leukocytes can be trapped in a platelet concentrate using the 
Choukroun PRF preparation method (Dohan Ehrenfest et al., 2010b).  
When compared to traditional PRP, PRF shows a higher concentration of growth factors, 
including platelet-derived growth factor-BB (PDGF-BB) and tissue growth factor-ß-1 
(Gassling et al., 2010; He et al., 2009; Kang et al., 2010). Because no additional activators are 
used during the preparation of PRF, the material undergoes a slower polymerization 
reaction than other forms of PRP, thereby allowing it to trap a number of key cytokines that 
would otherwise be lost. These cytokines, essential for healing, have been shown to be 
released sustainably (over a longer time) than in other PRP preparations, in so doing 
optimizing healing over a longer period. In a study by He et al (2009), the effect of PRF and 
PRP was tested on rat osteoblasts over a period of 28 days. It was found that PRF released 
 
 
 
 
  
autologous growth factors gradually over this period and had a significantly greater ability to 
induce mineralization when compared to PRP.  
Several researchers have studied the clinical and biological effects of PRF on wound healing. 
The grafting potential of PRF was researched by Jang et al (2010) when he studied the effect 
of combining PRF with silk powder to treat peri-implant bone defects. The results from this 
animal study indicate that PRF in combination with silk powder could successfully be used to 
manage these defects. Shen et al (2008) studied the effect of PRF on cultured periodontal 
cells and concluded that it had the ability to inhibit epithelial cell growth, enhance 
osteoblast proliferation, and increase gingival fibroblast proliferation.  
Choukroun et al (2006b) evaluated the potential of PRF in combination with freeze-dried 
bone allograft (FDBA) to enhance bone regeneration in lateral sinus floor elevation. Nine 
sinus floor augmentations were performed with 6 sinuses receiving PRF + FDBA particles 
(test group) and 3 sinuses receiving FDBA without PRF (control group). Four months after 
implantation (test group) and 8 months later (control), bone specimens were harvested with 
a 3-mm diameter trephine needle during implant insertion. Histologic evaluations revealed 
the presence of residual bone particles surrounded by newly formed bone and connective 
tissue. At 4 months, the histologic maturation of the test group appeared identical to that of 
the control group after a period of 8 months, with the quantities of newly formed bone 
equivalent between the two protocols. The use of PRF in combination with FDBA to perform 
sinus floor augmentation seemed to accelerate bone regeneration.  
The PRF membrane  
Unlike traditional PRP, PRF can be manipulated into a usable surgical membrane without the 
addition of animal derivatives (Dohan Ehrenfest et al., 2010b; Gassling et al., 2010; Aroca et 
al., 2009). Two methods to produce membranes from PRF have been described. These 
include; 
1. Compression with sterile gauze 
With this method, the PRF clot, once removed from the blood collecting tube, is compressed 
with hand/finger pressure between two sterile pieces of gauze on a flat surface thereby 
 
 
 
 
  
driving out most of the fluid until a yellow-white membrane is produced (Toffler et al., 2009; 
Dohan Ehrenfest et al., 2010b). 
2. The use of a PRF Box® 
The PRF Box® (Process Ltd., Nice, France), first described by Toffler et al (2009), is a 
commercially available metal box designed to form PRF membranes in less than one minute 
(Figure 4) The design is based on a perforated metal tray onto which the freshly prepared 
PRF clot is placed. The clot is then compressed with the lid, driving out most of the fluids 
and resulting in a yellow-white membrane for clinical use. The exudate collected at the 
bottom of the box may be used to hydrate graft materials, rinse the surgical site, and store 
autologous grafts (Toffler et al., 2009, Dohan Ehrenfest et al., 2010c). 
 
Figure 4: The PRF Box® (Toffler et al., 2009) 
A recent morphological assessment of the PRM membrane produced the following results 
(Dohan Ehrenfest et al., 2010b); 
• The PRM membrane was similar to the PRF in cellular distribution  
• Its configuration consisted mostly of dense fibrin arranged in parallel chords  
• The cellular composition was assumed to be the same as the PRF clot 
• The cellular distribution showed that platelets and leukocytes were concentrated 
near the red blood cell interface 
 
 
 
 
  
PRF: Clinical applications 
In a case report by Anilkumar et al (2009), a PRF membrane was used in conjunction with a 
lateral sliding flap to successfully restore buccal soft tissue recession on a single anterior 
lower incisor tooth. The patient initially presented with gingival recession of 5 mm. After the 
surgical site was prepared, a PRF membrane derived from the patient’s own blood was used 
to cover the exposed root area. This was then closed with a pedicle flap gained from the 
adjacent tooth. A 6-month clinical follow up showed complete root coverage with excellent 
colour and gingival contour. 
Del Corso et al (2009) confirmed this clinical application when he published several case 
reports showing the successful use of PRF membranes in the management of both single 
and multiple gingival recession defects. Using multiple PRF membranes, instead of 
connective tissue grafts, Del Corso et al (2009) was able to restore the lost soft tissue 
successfully by layering the PRF membranes over each other thereby increasing gingival 
height and thickness. The clinical results were maintained successfully for at least one year 
(Del Corso et al., 2009). 
In a clinical study over six months, Mazor et al (2009) showed that PRF could be used as the 
sole grafting material in sinus augmentation procedures (Mazor et al., 2009). In a similar 
study, Diss et al (2008) evaluated the radiographic changes in the apical bone levels of 20 
patients treated with 35 microthreaded implants placed using the Osteotome Mediated 
Sinus Floor Elevation technique. PRF was the sole grafting material used. Despite a limited 
residual subantral bone height (RSBH) of 4.5 to 8 mm, a healing period of 2-3 months was 
found to be sufficient to resist a torque of 25 N·cm applied during abutment tightening. One 
implant failed during the initial healing, but at one year, 34/35 implants were clinically 
stable and the definitive prostheses were in function, resulting in a survival rate of 97.1%. 
The mean sinus bone gain was 3.2 mm with radiographic documentation of apical 
displacement of the sinus floor (Diss et al., 2008). Other authors have had similar results 
using similar protocols (Simonpieri et al., 2011, Simonpieri et al., 2009b, Toffler, et al., 
2010). 
Using radiographic analysis, Mazor et al (2009) tested the efficacy of using PRF as barrier 
membranes to close windows created in the lateral maxillary sinus wall after sinus 
 
 
 
 
  
augmentation procedures. In the 9 cases where bone biopsies were harvested in the area of 
the window, no connective tissue invagination was observed, and bone samples were all 
very dense. This indicated that PRF was able to successfully protect the sinus graft area from 
the ingress of soft tissue. From the results of this study, Mazor et al (2009) concluded that 
PRF may be used to replace xenogenic and collagen membranes that are commonly used for 
this procedure. 
Because of the biological properties of PRF, several authors have attempted to use it in 
combination with bone substitutes to enhance healing during GBR procedures. Simonpieri 
et al (2009a), reported on a new technique for maxillary reconstruction using freeze-dried 
bone allograft (FDBA), PRF membranes and 0.5% metronidazole solution. PRF fragments 
were mixed with the graft particles, thereby functioning as a “biological connector” 
between the different elements of the graft. Using the reported protocol, they observed a 
high degree of gingival maturation after healing with a thickening of keratinized gingival 
tissues. In addition, they emphasized that the use of PRF seemed to reduce postoperative 
pain and oedema, and limited minor infections (Simonpieri et al., 2009a). 
Toffler et al (2009) using a similar PRF-bone graft mixture to successfully augmented a 
narrow alveolar ridge for future implant placement. In this GBR procedure, the PRF 
membrane was fragmented to mix easily with the bone graft material and further PRF 
membranes were placed over the graft material to isolate the wound. 
Alveolar ridge preservation or socket preservation is the term given to procedures that 
attempt to preserve bone at sites of tooth extraction. Several techniques exist, the most 
common being the placement of a bone grafting material in a freshly extracted tooth 
socket, followed by covering the socket with a collagen membrane or connective tissue 
graft. In a technique described by Toffler et al (2009), a PRF membrane can be compressed 
into a “plug” using the PRF Box® and used as a grafting material to fill recently extracted 
tooth sockets. The authors claim that this can be used to expedite soft tissue healing and 
allow for ideal implant placement. Other case reports have recently confirmed this 
phenomenon (Peck et al., 2011) 
PRF membranes have been used to repair perforations of sinus membranes after injury 
during sinus augmentation procedures. Choukroun et al (2006b) showed that sinus 
 
 
 
 
  
membrane perforations were successfully treated with PRF membranes thereby allowing 
sinus augmentation procedures to be completed successfully. In a similar study, Mazor et al 
(2009) showed that these perforations were completely sealed after sixth months and no 
adverse effects were noted during the healing process. Mazor et al (2009), therefore, 
concluded that the use PRF membranes was a viable treatment option in the management 
of iatrogenic sinus perforations (Mazor et al., 2009).  
The biological stability of PRF 
In order to gain maximum clinical efficacy from the use of PRF, its biological and structural 
properties requires stability over a period of time. Su et al (2009) proposed several 
techniques to improve the properties of PRF, including using it immediately after formation 
as well as using an impermeable material rather than cotton gauze to construct the PRF 
membrane. Other authors have suggested using a PRF box as the ideal storage medium to 
preserve the properties of PRF. This is based on the opinion that when PFR is stored in its 
centrifuging tube, it disintegrates after 15 minutes and becomes unusable as a biological 
material (Dohan Ehrenfest et al, 2010c). However, no known research has been published 
verifying this phenomenon.  
Current controversies regarding PRP and PRF 
Although widely used in a variety of clinical fields, the ability of PRP to enhance wound 
healing has recently been questioned (Wang et al, 2008; Trombelli et al, 2008; Plachkova et 
al, 2008). A systematic review of more than 100 papers concluded that significant evidence 
existed for the use of PRP in periodontal defects. However the same study concluded that 
the effect of PRP on sinus augmentation was less than 10% when compared to controls and 
suggested that no substantial evidence existed for its use in other dental procedures 
(Plachkova et al, 2008). The heterogeneity in studies that examine PRP is regarded as a 
major cause for the lack of conclusive evidence available for its use (Wang et al, 2007).  
PRF is a new form of platelet concentrate which has features that are distinctly unique when 
compared to PRP and therefore cannot be regarded as the same biomaterial. Although as 
mentioned previously the material has shown beneficial effects in a number of clinical case 
reports, it however suffers from the same scientific weaknesses as PRP in that the product 
 
 
 
 
  
currently lacks long term controlled trials that would endorse its routine use in surgical 
procedures. Recently, 5-year follow up reports have been published which demonstrates 
the clinical safety and efficacy of using this new biomaterial (Simonpieri et al, 2011). We 
await further such reports. 
In Summary 
PRF is reported to have a wide range of clinical applications. This is thought to be related to 
its biological properties that allow it to act as both a membrane as well as a platelet-
concentrate. Its preparation requires neither specialised equipment nor the addition of 
animal-derived products. However, questions remain regarding the best form of storage for 
freshly prepared PRF, and further research is required to better understand the ideal 
mechanism to retain its reported biological properties. 
  
 
 
 
 
  
Chapter 3 
Aims and Objectives 
Aim 
To determine whether storage time had a significant effect on the platelet concentration of 
Choukroun’s PRF. 
Objectives 
To determine the: 
a) platelet concentration of non-centrifuged blood  
b) platelet concentration of the residual blood immediately after Choukroun’s PRF 
formation and subsequent removal from the blood collecting tube 
c) platelet concentration of the residual blood after removal of Choukroun’s PRF from 
the blood collecting tube 60 minutes after it has been formed 
d) differences in platelet concentration between (b) and (c)  
Null hypothesis 
Storage time has no significant effect on the platelet concentration of Choukrouns PRF. 
Rationale 
Once prepared, Choukrouns PRF is often stored for a variable period of time before it is 
used. If the concentration of platelets in PRF remains constant during that time, then the 
potential for variation in clinical outcomes during a surgical procedure may be minimised. 
  
 
 
 
 
  
Chapter 4 
Materials and Methods 
Study design 
A cohort analytical study was used to conduct the research described in this thesis. 
Sample size 
A total of 30 patients were enrolled in the study. For each volunteer, three (3) blood 
samples of 10 ml each, were obtained from an antecubital vein by a professional nurse. Two 
(2) of these tubes were used as test samples and the remaining sample was used to 
measure baseline platelet concentration of the patients. A total of 90 independent freshly 
acquired human blood samples was thus analysed. The test samples were randomly divided 
into equal groups of 30 samples each (using a simple coin toss), designated Group A and 
Group B, respectively. 
Materials and Method 
1. After informed consent had been obtained, blood samples were collected at the 
Dental Faculty, University of the Western Cape, Tygerberg Hospital Campus from 30 
healthy volunteers (age range: 20 to 70 years, mean age: 45 years) who had no 
acquired or congenital defects that might interfere with normal coagulation. The 
blood samples were divided into groups as mentioned above. Sixty (60) silica-coated 
plastic tubes (Vacuette® 10 ml serum tubes with Z Serum Clot Activator, Greiner Bio 
One International AG, Germany) were used to collect the test samples (Figure 5). 
Thirty (30) ethylenediaminetetraacetic acid (EDTA)-coated tubes (BD Vacutainer® 
K2EDTA 10 ml) were used to collect the baseline samples.  
2. After blood collection, the test samples were centrifuged at 400 X g for 12 minutes, 
using a standard tabletop centrifuge (PLC-03, Hicare international, Taiwan) (Figure 
6).  
3. For all samples of Group A, the resultant PRF clot was immediately removed from 
the tube using sterile tweezers and separated from the red blood cell layer base 
using surgical scissors. 
 
 
 
 
  
 
 
 
 
Figure 5: Blood collecting tube 
 
 
 
Figure 6: Tabletop centrifuge  
 
 
 
 
  
4. For all samples of Group B, the resultant PRF clot was removed only after 60 minutes 
of storage in the original collecting tube.  
5. Immediately after removal of their respective PRF clots, the serum platelet 
concentrations of both Groups A and B were measured using an electronic 
automated cell counter (Advia 2120, Siemens AG, Erglangen, Germany). 
6. The platelet concentrations of the baseline samples were measured as described 
above. 
Data collection 
Data were collected and entered into a spreadsheet (Microsoft Office 2010 Excel, Microsoft 
Corporation, Washington). 
Data Processing and Analysis 
The results were compared and analysed using SPSS® Version 13 for Windows.  
For each group, the mean and standard deviation of platelet concentration was calculated. 
The following statistical tests were applied: 
 multiple analysis of variance  
 a multiple comparison test to determine the significance of differences among the 
means at a significance level of p = 0.05. 
Ethics 
The study was conducted under the principles outlined by the “World Medical Association 
Declaration Of Helsinki, Ethical Principles for Medical Research Involving Human Subjects” of 
2008. Ethical approval was obtained from the Ethics Committee of the University of the 
Western Cape (Registration number 11/4/29). All patients were fully informed of the 
research protocol and had to sign a declaration of informed consent before being allowed to 
participate in the study. All significant results obtained from this study will be submitted for 
publication in a relevant dental or medical journal. 
  
 
 
 
 
  
Chapter 5 
Results 
Study participants 
A total of 30 patients (16 females and 14 males) were enrolled into the study. The mean age 
of the participants was 41.7 years, with male subjects being slightly younger than their 
female counterparts (41.3 years for males vs 42 years for females). The youngest participant 
was 24 years old and the oldest 58 years old (Table 1). 
 
 
Table 1: Age and gender of study participants 
 
  
The platelet concentration of non-centrifuged blood (baseline concentrations) 
Platelet concentrations obtained from haematologic analysis of all 30 samples fell within the 
normal laboratory reference range of 170-400 × 109/L of circulating blood and no 
participants displayed any significant haematological disease (Figure. 7). The mean blood 
platelet concentration was 282.8 × 109/L, the median 282 × 109/L, and the standard 
deviation was 58.3 × 109/L. The 95% confidence interval estimate for the mean was (261.0 
to 304.6) (Table 2). 
  
Number of participants 
 
Mean age and standard 
deviation in years 
 
Age range in years 
 
Male 
 
14 
 
41.43 ± 10.50 
 
27.00 - 58.00 
 
Female 
 
16 
 
41.94 ± 10.25 
 
24.00 - 55.00 
 
Total 
 
30 
 
41.70 ± 10.19 
 
24.00 - 58.00 
 
 
 
 
  
 
Figure 7: Baseline concentration of non-centrifuged blood 
The platelet concentration of residual blood after removal of Choukroun’s PRF 
(immediately after formation, Group A) 
After removal of Choukroun’s PRF, the residual blood yielded minimal concentrations of 
platelets. The mean concentration of platelets obtained was 7.9 × 109/L with a median of 
8.0 × 109/L and a standard deviation of 3.03 × 109/L. The 95% confidence interval estimate 
for the mean was ( 6.76 to 9.32) (Table 2).  
The platelet concentration of residual blood after removal of Choukroun’s PRF (60min 
after formation, Group B) 
As in Group A, blood platelet concentrations were minimal after removal of Choukroun’s 
PRF. The mean concentration of the platelets was 4.0 × 109/L with a median of 4.0 ×109/L 
and a standard deviation of 1.93 × 109/L. The 95% confidence interval estimate for the mean 
was (3.27 to 4.72) (Table 2). The mean platelet concentration of Group B was higher than 
that determined for Group A. 
 
 
 
 
 
  
Table 2: Platelet concentrations for the various groups tested 
Groups Number Mean and standard 
deviation in  cells × 109/L of 
blood 
Confidence 
interval 
 
Baseline 
 
30 
 
282.8 ± 58.27 
 
261.04 to 304.56 
 
Group A (0 Min) 
 
30 
 
7.90 ± 3.33 
 
6.76 to 9.03 
 
Group B (60 Min) 
 
30 
 
4.00 ± 1.93 
 
3.27 to 4.72 
 
Difference between Group 
A and Group B 
 
30 
 
3.90 ± 3.13 
 
2.73 to 5.07 
 
Analysis of the differences in platelet concentrations of Group A and Group B 
From the descriptive analysis, it is clear that Group B yielded lower platelet concentrations 
than Group A. The mean difference in platelet concentrates between the 2 groups was 3.90 
× 109/L with a median of 3.5 × 109/L and standard deviation of 3.13 × 109/L. The 95% 
confidence interval estimate for the mean was 2.73 to 5.06) (Table 2). 
 
Using a non-parametric Signed Rank Test, the statistical significance of the differences in 
platelet concentrates between the Groups A and B was analysed (Figure 8). The difference 
between the 2 groups was statistically significant (p < 0.0001) with a point estimate of the 
amount of difference of 3.9 units and a 95% confidence interval of 2.7 to 5.1. From the 
statistical analysis we, therefore, concluded that there is a significant difference in the mean 
concentration of PRF between time 0 and time 60 minutes. 
  
 
 
 
 
  
 
Figure 8: Residual platelet concentration of Groups A and B 
 
The difference in initial and residual platelet concentration indicates that more than 90% of 
the available platelets were trapped in the PRF after the blood was centrifuged.  
  
 
 
 
 
  
Chapter 6 
Discussion and Conclusions 
The purpose of this study was to determine whether storage time had any significant effect 
on the platelet concentration of Choukroun’s PRF. Because the structural properties of the 
PRF clot does not allow for a direct measurement of its platelet concentration, we used the 
residual platelet values left in the blood tube after removal of the PRF clot, as an indirect 
measurement of the platelet concentration in the PRF clot. Higher residual values indicate 
that less platelets were contained in the removed clot whereas lower residual values would 
indicate that more platelets were transferred to the clot. A similar study was carried out by 
Dohan Ehrenfest et al (2010b). 
From the platelet counts obtained in both test groups it was clear that a significant amount 
of platelets had been removed from the blood after extraction of the PRF clots. In fact, 
when differences between the test groups and the baseline blood sample were compared, it 
was evident that more than 97-98% of the platelets were concentrated in the PRF clot. This 
observation is similar to results published for previous studies (97%) and thus validates the 
method of PRF production used in the experiment (Dohan et al, 2006). The natural process 
of fibrin and clot formation that occurs in the blood collecting tubes results in the 
entrapment of the majority of the available platelets in a fibrin matrix. This may act as a 
reservoir for a concentration of growth factors required in the initial stages of wound 
healing. 
Although the physiology of Choukroun’s PRF has been studied extensively, very few reports 
adequately document the ability of this platelet concentrate to be stored. Previous research 
has indicated that storing Choukroun’s PRF under certain conditions may affect its ability to 
clinically yield positive results. In fact it is not recommended to store the platelet 
concentrate in its blood collecting tube since it is assumed that it may disintegrate into an 
unsuable form after about 15 minutes of storage time (Dohan Ehrenfest et al, 2010). 
Instead, several authors recommend storing the agent in a metal dish or a propriety 
designed storage box. Data regarding the maximal storage time and ideal storage 
temperature of PRF are largely lacking. 
 
 
 
 
  
In our study, we used standard blood collecting tubes with clot activators to store PRF for at 
least 60 minutes at room temperature. This particular length of time was chosen based on 
the average time of typical periodontal surgical procedures at our facility. The results of the 
study indicate that by using Choukroun’s protocol for platelet concentrate preparation, it 
was possible to concentrate more than 97% of the available blood platelets into a readily 
usable form. This study also showed that by using the blood collecting tubes as a storage 
medium, that there was no detrimental effect on the platelet concentration of Choukroun’s 
PRF. Indeed, storing the concentrate for 60 minutes in these tubes resulted in a form of 
Choukroun’s PRF that had significantly higher concentrations of platelets compared to their 
non-stored counterparts. The reason for this phenomenon is unknown, but may be related 
to the “clot activators” that line these tubes. Clot activators are often silica based and are 
used in plastic tubes to mimic the clotting effect of glass based blood tubes. As a result, a 
longer contact time between blood and these activators may encourage fibrin activation 
and clot formation, with subsequent platelet entrapment.  
Another reason for variation in platelet concentration seen in this study may be due to the 
fact that the recommended centrifuge time is too short to allow for complete clot formation 
to take place. Therefore, allowing the PRF clot to remain in the tube for a period longer than 
the recommended time, may result in a more complete physiological reaction taking place. 
The ability of Choukroun’s PRF to sustain its platelet concentrate over the tested time may 
have significant clinical implications. Rather than drawing blood at least 15 minutes before 
the PRF is required in a surgical procedure, it allows for blood to be drawn before the start 
of the procedure, thereby improving patient comfort and operator time. The ability to store 
the PRF in the same tubes in which it was formed, negates exposure to other environmental 
factors that may contaminate the sample. It is also cost-effective, since no specialised 
equipment or storage facilities are required. This may be significant in resource poor 
settings.  
PRF has been recognised as a biomaterial that includes living cells (Dohan et al.,2006). In 
order to sustain cell viability over time, an isotonic solution is required for their storage. The 
blood collecting tubes, although not designed to store blood, act as containers for the PRF 
and the remaining cells and serum. Consequently, by storing PRF in the blood that it was 
 
 
 
 
  
derived from, the remaining serum, after PRF has formed, acts as a natural isotonic solution 
that sustains cell survival. 
The release of growth factors is a significant property of blood platelets (Kang et al., 2011). 
Previous studies indicate that several of these factors play an essential role in osteogenesis 
and periodontal regeneration (Shen et al., 2008; Gassling et al., 2010). By using PRF, the 
release of these growth factors appears to be constant, and over a longer period of time 
when compared that seen by PRP (He et al., 2009). In a direct comparison between the two, 
PRP was shown to have an initial larger release of growth factors after activation. However, 
these high concentrations were not stable and decreased over time. On the other hand, PRF 
releases less growth factors initially, but sustains this release for a longer duration (He et al., 
2009). A number of authors speculate that this may be due to the fibrin clot that forms a 
network and acts as a reservoir for the trapped platelets (Dohan et al., 2006; Dohan 
Ehrenfest et al., 2010b; Toffler et al., 2009). In the present study, it was shown that the 
platelet concentration of PRF improved over a period of 60 minutes of storage. We assume 
that this may be due to prolonged fibrin clot maturation. It is therefore reasonable to 
speculate that if PRF is stored until optimal fibrin formation is achieved, then higher 
concentrations of growth factors may be available from the PRF during wound healing. 
Whether this has any clinical significance requires further investigation. 
Temperature may affect the storage potential of PRF and criticism has been levelled 
towards storing it in near-freezing temperatures (Del Corso et al., 2009). In this study, all the 
samples were stored at room temperature. From the data collected, it was clear that 
storage under these conditions has no detrimental effect on the platelet concentration of 
the PRF clot. 
Although the present study showed statistically significant differences between the two 
groups tested, several limitations were also evident. These include the limited number of 
study participants as well as the inability to directly measure the platelet concentration of 
PRF. Other factors include the small difference between the platelet concentrations of the 
groups tested. Although statistically significant, a mean difference of only 3.9 × 109 cells/L 
may not be clinically relevant and therefore warrants further research to validate the clinical 
significance of these findings. 
 
 
 
 
  
Conclusions 
 
The viability of storing PRF in its own blood collecting tubes has not yet been reported. This 
study showed that by using Choukroun’s method of platelet preparation it is possible to 
concentrate more than 97% of the available platelets into a PRF clot. The study also 
indicated that, unlike previous reports, clot disintegration does not take place after 15 
minutes of storage, but rather remains stable over a period of at least 60 minutes and may 
in fact increase in platelet concentration during that time. The null hypothesis of this study 
has therefore been rejected and it may be concluded that storage time does have a 
significant effect on the platelet concentration of PRF. This was an unexpected finding, and 
further investigations are required to elicit whether this has any clinical significance.  
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